Compare OII & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OII | WGS |
|---|---|---|
| Founded | 1964 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | N/A | N/A |
| Metric | OII | WGS |
|---|---|---|
| Price | $24.68 | $163.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $25.00 | ★ $130.63 |
| AVG Volume (30 Days) | ★ 744.0K | 507.1K |
| Earning Date | 10-22-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.60 | N/A |
| EPS | ★ 2.29 | 0.07 |
| Revenue | ★ $2,829,032,000.00 | $402,190,000.00 |
| Revenue This Year | $5.78 | $39.54 |
| Revenue Next Year | $1.81 | $22.50 |
| P/E Ratio | ★ $10.78 | $2,224.81 |
| Revenue Growth | 8.71 | ★ 50.50 |
| 52 Week Low | $15.46 | $55.17 |
| 52 Week High | $30.98 | $170.75 |
| Indicator | OII | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 59.67 | 70.80 |
| Support Level | $22.77 | $119.43 |
| Resistance Level | $24.95 | $170.75 |
| Average True Range (ATR) | 0.74 | 9.12 |
| MACD | 0.14 | 2.99 |
| Stochastic Oscillator | 85.07 | 86.07 |
Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.